Neuronetics Inc (STIM)

$ 13.56
0.51 (+3.91%)
-
Symbol STIM
Price $ 13.56
Beta 2.678
Volume Avg. 0.49M
Market Cap 0.35B
Shares () -
52 Week Range 1.7-22.43
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -41.93% Strong Sell
ROA -12.69% Sell
Operating Margin -
Debt / Equity 49.36% Neutral
P/E -
P/B 3.34 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Neuronetics, Inc (NVO) CEO Keith Sullivan on Q1 2021 Results - Earnings Call Transcript

Neuronetics, Inc (NVO) CEO Keith Sullivan on Q1 2021 Results - Earnings Call Transcript

Neuronetics, Inc (NVO) CEO Keith Sullivan on Q1 2021 Results - Earnings Call Transcript ...

Seeking Alpha
Neuronetics (STIM) Soars 39.2%: Is Further Upside Left in the Stock?

Neuronetics (STIM) Soars 39.2%: Is Further Upside Left in the Stock?

Neuronetics (STIM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. ...

Zacks Investment Research
Why Neuronetics Blasted 39% Higher Today

Why Neuronetics Blasted 39% Higher Today

The company is experiencing a strong rise in demand. ...

The Motley Fool
STIM Stock: From $10.15 To $11.64 (14.7 Increase) Intraday Explanation

STIM Stock: From $10.15 To $11.64 (14.7 Increase) Intraday Explanation

The stock price of Neuronetics Inc (NASDAQ: STIM) increased from $10.15 to a day high of $11.64 during intraday trading this morning. This is why it happened. ...

Pulse2
Neuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of its Board of Directors

Neuronetics Announces Retirement of Brian Farley and Appointment of Robert Cascella as Chairman of i...

MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psy... ...

GlobeNewsWire
Neuronetics Announces Appointment of Robert Cascella to its Board of Directors

Neuronetics Announces Appointment of Robert Cascella to its Board of Directors

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psy... ...

GlobeNewsWire
Neuronetics Announces Retirement of Gregory Harper, Vice President, R&D and Clinical

Neuronetics Announces Retirement of Gregory Harper, Vice President, R&D and Clinical

MALVERN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from ps... ...

GlobeNewsWire
Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2020 Results - Earnings Call Transcript

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2020 Results - Earnings Call Transcript

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2020 Results - Earnings Call Transcript ...

Seeking Alpha
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 24.00% and 2.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? ...

Zacks Investment Research
Neuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

Neuronetics Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psy... ...

GlobeNewsWire

About


Mr. Christopher Thatcher
Healthcare
Diagnostics & Research
Nasdaq Global Select

Neuronetics, Inc. commercial stage medical technology company. The company is headquartered in Malvern, Pennsylvania and currently employs 191 full-time employees. The firm is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. The company is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The firm offers its therapy systems to psychiatrist offices in the United States.